Insights

Strategic partnerships TheraVectys maintains a joint-laboratory model with the Institut Pasteur, signaling a strong openness to collaboration with research institutions and potential co-development opportunities for lentiviral vector platforms, vaccines, and immunotherapies.

Vaccine and immunotherapy focus With a pipeline centered on lentiviral vector–based vaccines and immunotherapies for cancer and infectious diseases, there are multiple entry points for partnerships in preclinical and clinical development, as well as supply deals for vector manufacturing and delivery.

Global footprint Operates in Paris and the USA, indicating readiness for cross-border clinical programs, regulatory navigation support, and access to diverse funding sources and local partnerships in North America and Europe.

Funding signal Recent financing of twenty million dollars and a total funding of fifty-one million dollars, combined with revenue under one million, suggests investor interest in early-stage immunotherapy platforms and potential for strategic funding rounds or milestones tied to pipeline progress.

Technology leverage Proprietary lentiviral vector technology and deep virology expertise position Theravectys as a potential supplier or collaborator for vector production services, transfection optimization, and immune response engineering for partner programs.

Similar companies to THERAVECTYS

THERAVECTYS Tech Stack

THERAVECTYS uses 8 technology products and services including WordPress, Shopify, Microsoft 365, and more. Explore THERAVECTYS's tech stack below.

  • Content Management System
  • E-commerce
  • jQuery
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • Windows Server
    Operating Systems
  • Platform As A Service
  • FitVids.js
    Web Tools And Plugins

THERAVECTYS's Email Address Formats

THERAVECTYS uses at least 3 email formats:
THERAVECTYS Email FormatsExamplePercentage
FLast@theravectys.comJDoe@theravectys.com
79%
First.Last@theravectys.comJohn.Doe@theravectys.com
19%
FMiddleLast@theravectys.comJMichaelDoe@theravectys.com
2%

Frequently Asked Questions

What is THERAVECTYS's phone number?

Minus sign iconPlus sign icon
You can contact THERAVECTYS's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is THERAVECTYS's official website and social media links?

Minus sign iconPlus sign icon
THERAVECTYS's official website is theravectys.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does THERAVECTYS generate?

Minus sign iconPlus sign icon
As of October 2026, THERAVECTYS's annual revenue is estimated to be <$1M.

What is THERAVECTYS's SIC code and NAICS code?

Minus sign iconPlus sign icon
THERAVECTYS's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does THERAVECTYS have currently?

Minus sign iconPlus sign icon
As of October 2026, THERAVECTYS has approximately 17 employees across 3 continents, including Europe, North America and Asia. Key team members include Chief Representative: A. H., Trilingual Executive Assistant To Ceo: J. L. and Director Clinical Operations: E. B. Explore THERAVECTYS's employee directory with LeadIQ.

What industry does THERAVECTYS belong to?

Minus sign iconPlus sign icon
THERAVECTYS operates in the Biotechnology Research industry.

What technology does THERAVECTYS use?

Minus sign iconPlus sign icon
THERAVECTYS's tech stack includes WordPress, Shopify, Microsoft 365, jQuery, Modernizr, Windows Server, Microsoft Azure and FitVids.js.

What is THERAVECTYS's email format?

Minus sign iconPlus sign icon
THERAVECTYS's email format typically follows the pattern of FLast@theravectys.com. Find more THERAVECTYS email formats with LeadIQ.

How much funding has THERAVECTYS raised to date?

Minus sign iconPlus sign icon
As of October 2026, THERAVECTYS has raised $51M in funding. The last funding round occurred on Feb 08, 2021 for $20M.

When was THERAVECTYS founded?

Minus sign iconPlus sign icon
THERAVECTYS was founded in 2005.
THERAVECTYS logo

THERAVECTYS

Biotechnology ResearchÎle-de-France, France11-50 Employees

TheraVectys is a biotechnology research company specializing in immunotherapy, with activities in Paris and the United States. Headquartered in Paris at 28 Rue du Docteur Roux (75015), the company employs between 11 and 50 people. TheraVectys originated as a spin-off of the Institut Pasteur, which Dr. Pierre Charneau helped establish in 2005. It uses lentiviral vector technology as its core platform to develop vaccines and immunotherapies, building a pipeline addressing cancer and infectious diseases. The company operates the only Joint-Laboratory between a private company and the Institut Pasteur in Paris. In 2021 the company announced a financing round.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2005
Employees
11-50

Section iconFunding & Financials

  • $51M

    THERAVECTYS has raised a total of $51M of funding over 4 rounds. Their latest funding round was raised on Feb 08, 2021 in the amount of $20M as a Venture Round.

  • <$1M

    THERAVECTYS's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.